Abstract: A vehicle information transmission system that carries out communication with a management server that manages a vehicle includes an electronic control unit. The electronic control unit is configured to acquire vehicle information in accordance with a third sampling pattern that is a combination of a first sampling pattern and a second sampling pattern. The vehicle information is transferred within an in-vehicle network installed in the vehicle. The first sampling pattern is a sampling pattern in which the vehicle information is sampled at a change point at which a predetermined change has occurred. The second sampling pattern is a sampling pattern in which the vehicle information is sampled at intervals of a predetermined period. The electronic control unit is configured to transmit the acquired vehicle information to the management server.

Abstract: A vehicle information transmission system that carries out communication with a management server that manages a vehicle includes an electronic control unit. The electronic control unit is configured to acquire vehicle information in accordance with a third sampling pattern that is a combination of a first sampling pattern and a second sampling pattern. The vehicle information is transferred within an in-vehicle network installed in the vehicle. The first sampling pattern is a sampling pattern in which the vehicle information is sampled at a change point at which a predetermined change has occurred. The second sampling pattern is a sampling pattern in which the vehicle information is sampled at intervals of a predetermined period. The electronic control unit is configured to transmit the acquired vehicle information to the management server.

Abstract: A device (HS) is provided with a refrigeration cycle unit (R) and a liquid hydrogen generation unit (P) for generating liquid hydrogen by cooling high-pressure raw material hydrogen by means of the refrigeration cycle unit (R) and by adiabatically expanding said raw material hydrogen by means of a Joule-Thomson valve (12). A first and second heat exchanger (E1, E2) are disposed along the refrigeration cycle unit (R) and the liquid hydrogen generation unit (P). The device (HS) is provided with a mechanism for generating liquid hydrogen by re-liquefying the boil-off gas generated in a liquid hydrogen storage tank. The boil-off gas is introduced into a hydrogen circulation path (1) at a section at which circulating hydrogen having an extremely low temperature flows, and the excessive circulating hydrogen generated therefrom is discharged to a raw material hydrogen path (11) from a section at which the circulating hydrogen is at room temperature.

Abstract: The boil-off gas discharged from a liquid hydrogen storage tank on a liquid hydrogen transport vessel (16) is introduced into the liquid hydrogen stored within liquid hydrogen storage tanks (19, 20) disposed on the ground by passing through a boil-off gas introduction path (17). At least a portion of the boil-off gas is re-liquefied by means of the cold temperature of the liquid hydrogen. The boil-off gas that was not re-liquefied and the gasified hydrogen generated as a consequence of the liquid hydrogen within the liquid hydrogen storage tanks (19, 20) gasifying are mixed with raw material hydrogen by being supplied to the raw material hydrogen path (11) of a liquid hydrogen production device (HS) by passing through a gasified hydrogen discharge path (21). The boil-off gas and the gasified hydrogen are re-liquefied by means of the liquid hydrogen production device (HS).

Abstract: There are provided a carbon fiber reinforced prepreg of gas barrier properties comprising a sheet-like carbon fiber reinforcement and a matrix resin including therein a gas barrier layer having a clay mineral with a plate-like crystal structure unidirectionally aligned and densely laminated, and a carbon fiber reinforced plastic produced from the carbon fiber reinforced prepreg. Such prepreg is obtained by disposing a film material of gas barrier properties having a clay mineral with a plate-like crystal structure unidirectionally aligned and densely laminated, in at least one interlayer of a laminate of a carbon fiber reinforced prepreg comprising a sheet form carbon fiber reinforcement and a matrix resin; and then heating and/or pressurizing the laminate. The carbon fiber-reinforced composite material of the invention exhibits high gas barrier properties, and particularly hydrogen gas barrier properties.

Abstract: There are provided a carbon fiber reinforced prepreg of gas barrier properties comprising a sheet-like carbon fiber reinforcement and a matrix resin including therein a gas barrier layer having a clay mineral with a plate-like crystal structure unidirectionally aligned and densely laminated, and a carbon fiber reinforced plastic produced from the carbon fiber reinforced prepreg. Such prepreg is obtained by disposing a film material of gas barrier properties having a clay mineral with a plate-like crystal structure unidirectionally aligned and densely laminated, in at least one interlayer of a laminate of a carbon fiber reinforced prepreg comprising a sheet form carbon fiber reinforcement and a matrix resin; and then heating and/or pressurizing the laminate. The carbon fiber-reinforced composite material of the invention exhibits high gas barrier properties, and particularly hydrogen gas barrier properties.

Abstract: Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: Heterocyclic derivatives of the formula (I) 1

Abstract: Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: A heterocyclic derivative of the formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

Abstract: Heterocyclic derivatives of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors.To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: A heterocyclic derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

Abstract: Heterocyclic derivatives of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: An imidazole derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof is described. A method for producing the compound or its salt, and its pharmaceutical use, particularly as an agent for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine are described. Also, compounds of the formula (II) and (IV) ##STR2## wherein each symbol is as defined in the specification are described. The imidazole derivative and its parmacologically acceptable salt are useful as agents for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine, and the intermediate compounds (II) and (IV) are novel compounds.

Abstract: A heterocyclic derivative of the formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.